AminoAnalytica Analysis: $500K Raised
What is AminoAnalytica?
AminoAnalytica develops point-of-care molecular diagnostics for emerging biological threats, with a stated target of building them in weeks rather than more than 12 months. The company also describes itself as building AI scientists to support safer pandemic response through early prevention. Its public site names co-founders Abhi, formerly at Mercedes F1, and Adam, a Thermo Fisher Scholar and former Procter & Gamble employee, plus Chief Scientist Prof. Stefano Angioletti-Uberti of Imperial College London.
Location
London, United Kingdom
Employees
1-10
Founded
2024
Revenue
$750K
Investors
- Y Combinator
- Imperial Enterprise Lab
Product Features & Capabilities
- AI-powered protein optimization, state-of-the-art AI models, custom molecular simulations, in-vitro validation, human-in-the-loop process.
How much AminoAnalytica raised
Seed - $500K
2025Lead Investor: Imperial Enterprise Lab, Y Combinator
Market Focus
AminoAnalytica primarily focuses on the biotechnology industry, specifically in the area of AI-powered protein optimization for various applications.
Business Model
AI-driven protein optimization services for biotech firms, generating revenue through software subscriptions and consulting.
Competitors Overview
The main competitors of AminoAnalytica in the field of AI-powered protein optimization include:
-
Nimbus Therapeutics: This company focuses on using computational methods to design and optimize small molecules and proteins. Their advantage lies in their proprietary platform that integrates structural biology and machine learning to enhance drug discovery processes.
-
Schrodinger: Known for its software solutions that combine physics-based simulations with machine learning, Schrodinger provides tools for drug discovery and materials science. Their notable advantage is their extensive library of molecular modeling tools, which can be applied across various scientific fields.
-
Evozyne: This company specializes in protein engineering and optimization using AI and machine learning. Evozyne's advantage is its unique approach to creating novel proteins with desired functionalities, which can be tailored for specific applications in biotechnology and pharmaceuticals.
These competitors leverage advanced technologies and methodologies that may differ from AminoAnalytica's focus on AI-driven protein optimization, providing them with distinct advantages in their respective niches.
See something that needs updating? Suggest edits to this profile.